- 主條目:Synthetic small molecule and biological preparation合成小分子和生物製劑
- 常常當作標靶藥物、Rheumatism風濕病藥品
- 其實分成Synthetic small molecule合成小分子 and biological preparation生物製劑是出現在Rheumatism風濕病，只不過想說標靶藥物也是分成單株抗體(生物製劑)和nib(剛好也是合成小分子)，所以乾脆建立一個條目把他們都歸在下面。
- Growth factor receptor modulators in wikipedia 20170729
mechanism of monoclonal antibody and tyrosine kinase inhibitor
Rheumatism風濕病藥品[]
psoriasis乾癬[]
Inflammatory Bowel Disease發炎性腸道疾病IBS[]
見Inflammatory Bowel Disease發炎性腸道疾病IBS
[]
Bcr-Abl Kinase Inhibitors[]
- Imatinib Glivec®基利克 Tablet:(target: , biomarker: ,treat)
- Nilotinib(target: , biomarker: ,treat)
- Dasatinib(target: , biomarker: ,treat)
[]
~nib[]
- gefitinib(Iressa ®)艾瑞莎(target: , biomarker: ,treat)
- erlotinib(Tarceva ®)得舒緩(target: , biomarker: ,treat)
~mab[]
- anti-EGFR:cetuximab(Erbitux®)爾必得舒(target: , biomarker: ,treat)
- anti-EGFR:trastuzumab(Herceptin®)賀癌平:(target: , biomarker: ,treat) HER2 receptor(HER2/neu) positive disease.treat breast cancer.
- anti-EGFR:Panitumumab(Vectibix®)維必施(target: , biomarker: ,treat) : is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).It was approved by the U.S. Food and Drug Administration (FDA) for the first time in September 2006, for "the treatment of EGFR-expressing metastatic colorectal cancer with disease progression" despite prior treatment.[1] Panitumumab was approved by the European Medicines Agency (EMEA) in 2007, and by Health Canada in 2008 for "the treatment of refractory EGFR-expressing metastatic colorectal cancer in patients with non-mutated (wild-type) KRAS".
Panitumumab was the first monoclonal antibody to demonstrate the use of KRAS as a predictive biomarker.
others[]
未完成
EGFR and HER2 Kinase Inhibitors[]
[]
眼科用藥:anti-VEGF:因為缺血造成缺氧會使得細胞放出VEGF使得血管長向他提供氧氣。缺一張有版權圖所以不完整[]
~nib[]
- Sunitinib紓癌特Sutent®
- Pazopanib(target: , biomarker: ,treat)
- Sorafenib:肝癌(target: , biomarker: ,treat)
- Pegaptanib(Macugen)(目可健):歐洲用，打了以後視力也無法恢復，已經被欣一代的anti-VEGF取代。
- Nitendanib(target: TKI targeting angiogenesis-related transmembrane receptors , biomarker: ,treat lung fibrosis and lung cancer(外國2018))
~mab[]
- Bevacizumab癌思停Avastin®(target: recombinant humanized anti-VEGF monoclonal antibody , biomarker: ,treat) :anti-VEGF/R。molecule size大，可能不能過retina。20141116健保不給付眼用。一瓶兩萬，可以大家一起打，平均六千~八千元。
- Ranicizumab樂舒晴Lucentis®:類似Avastin，但是分子比較小，也比他不易有不良反應，但是效果差不多。一隻三萬。每個月注射一次。
- Ramucirumab(Cyramza®)(欣銳擇(target: fully human IgG1 monoclonal antibody to VEGF receptor-2 , biomarker: ,treat lung cancer)
others[]
- Aflibercept采視明Eylea®:VEGF trap
- anti-VEGF/R :不是~mab:Aflibercept賽諾菲 Zaltrap®:VEGF trap-2014 2line of CRC
multiple target TKI: SE多，手口足症HFS嚴重[]
~nib[]
- Regorafenib(Stivarga癌瑞格)(target: , biomarker: ,treat) :大腸癌、GIST 20143L and 3L+(3, 4, 5, 6L...etc.). anti-VEGF, too.
- P.S. Sunitinib Sutent®紓癌特 Capsule(target: , biomarker: ,treat) :GIST 20142Line
~mab[]
未完成
others[]
未完成
mTOR inhibitors[inhibitor of mammalian target of rapamycin (mTOR)].[]
- Temsirolimus(target: , biomarker: ,treat)
- Everolimus(target: , biomarker: ,treat)